C-reactive Protein and Erythrocyte Sedimentation Rate Discrepancies and Variations after Intravenous Immunoglobulin Therapy in Kawasaki Disease
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: We undertook this study to investigate discrepancies in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values, and variations following intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD). Methods: A total of 123 KD patients were retrospectively enrolled. Patients were treated with IVIG 2 g/kg at 2 to 9 days after disease onset. We obtained white blood cell (WBC) count, percentage of neutrophils (% neutrophils), CRP, ESR, and N-terminal pro-brain natriuretic peptide (NT-proBNP) values before and 48 to 72 hours after IVIG treatment. Discrepancy was defined as CRP ≥10 mg/dL and ESR <50 mm/ hr (Group 1), or CRP <10 mg/dL and ESR ≥50 mm/hr (Group 2). Results: Thirty-six of 123 subjects (29.2%) had a discrepancy: 25 (20.3%) in Group 1 and 11 (8.9%) in Group 2. In Group 1, 15 patients (60%) had fever for <5 days (early presenter) and 10 (40%) had fever for ≥5 days (late presenter). There were six early presenters (55%) and five late presenters (45%) in Group 2. Late presenters had higher ESR than early presenters (34.3±21.0 mm/hr vs. 26.3±19.3 mm/hr, P=0.029). After IVIG treatment, elevated WBC count, % neutrophils, CRP, and NT-proBNP levels normalized. In contrast, ESR increased from 37.4±21.9 mm/hr to 48.0±22.7 mm/hr (n=36, P=0.051). Conclusions: A discrepancy may be related to the duration of fever. Due to discrepancies in CRP and ESR values in acute KD, both should be measured to assess the degree of inflammatory activity before IVIG treatment. After IVIG treatment, the ESR should not be used as a marker of response to therapy in KD.
Abstract
Purpose: We undertook this study to investigate discrepancies in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values, and variations following intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD). Methods: A total of 123 KD patients were retrospectively enrolled. Patients were treated with IVIG 2 g/kg at 2 to 9 days after disease onset. We obtained white blood cell (WBC) count, percentage of neutrophils (% neutrophils), CRP, ESR, and N-terminal pro-brain natriuretic peptide (NT-proBNP) values before and 48 to 72 hours after IVIG treatment. Discrepancy was defined as CRP ≥10 mg/dL and ESR <50 mm/ hr (Group 1), or CRP <10 mg/dL and ESR ≥50 mm/hr (Group 2). Results: Thirty-six of 123 subjects (29.2%) had a discrepancy: 25 (20.3%) in Group 1 and 11 (8.9%) in Group 2. In Group 1, 15 patients (60%) had fever for <5 days (early presenter) and 10 (40%) had fever for ≥5 days (late presenter). There were six early presenters (55%) and five late presenters (45%) in Group 2. Late presenters had higher ESR than early presenters (34.3±21.0 mm/hr vs. 26.3±19.3 mm/hr, P=0.029). After IVIG treatment, elevated WBC count, % neutrophils, CRP, and NT-proBNP levels normalized. In contrast, ESR increased from 37.4±21.9 mm/hr to 48.0±22.7 mm/hr (n=36, P=0.051). Conclusions: A discrepancy may be related to the duration of fever. Due to discrepancies in CRP and ESR values in acute KD, both should be measured to assess the degree of inflammatory activity before IVIG treatment. After IVIG treatment, the ESR should not be used as a marker of response to therapy in KD.
참고문헌 (10)
- 이현주, "가와사끼병에서 진단적 지표로서의 NT-proBNP", Korean Journal of Pediatrics, 49(5), pp.539~544 (2006), 대한소아과학회
- Anderson MS, "Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease", Pediatr Infect Dis J, 20, pp.698~702 (2001)
- Dajani AS, "Diagnosis and therapy of Kawasaki disease in children", Circulation, 87, pp.1776~1780 (1993)
- 이고니, "Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease?", Korean Circulation Journal, 43(3), pp.182~186 (2013), 대한심장학회
- Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease, "Research committee on Kawasaki disease", Ministry of Health and Welfare, ~ (1984)
- Newburger JW, "Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association", Circulation, 110, pp.2747~2771 (2004)
- Kawasaki T, "Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children", Jpn J Allergy, 16, pp.178~222 (1967)
- Young B, "C-reactive protein: a critical review", Pathology, 23, pp.118~124 (1991)
- 김현권, "Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease", Korean Circulation Journal, 41(7), pp.379~384 (2011), 대한심장학회
- de Zorzi A, "Coronary artery dimensions may be misclassified as normal in Kawasaki disease", J Pediatr, 133, pp.254~258 (1998)